vs
Ispire Technology Inc.（ISPR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Ispire Technology Inc.的1.5倍（$30.3M vs $20.3M），Ispire Technology Inc.净利率更高（-32.5% vs -221.3%，领先188.8%），REGENXBIO Inc.同比增速更快（43.0% vs -51.5%），Ispire Technology Inc.自由现金流更多（$-4.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -17.8%）
Ispire科技是一家专注于先进雾化硬件及配套耗材研发、生产与销售的全球化科技企业，主要服务尼古丁及合法大麻消费市场，下设硬件、品牌大麻产品两大核心业务板块，覆盖北美、欧洲、亚太等核心市场，为B端合作商及终端用户提供合规创新的雾化解决方案。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ISPR vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$20.3M
营收增速更快
RGNX
高出94.5%
-51.5%
净利率更高
ISPR
高出188.8%
-221.3%
自由现金流更多
ISPR
多$48.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-17.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.3M | $30.3M |
| 净利润 | $-6.6M | $-67.1M |
| 毛利率 | 17.1% | — |
| 营业利润率 | -33.9% | -190.0% |
| 净利率 | -32.5% | -221.3% |
| 营收同比 | -51.5% | 43.0% |
| 净利润同比 | 17.4% | -31.2% |
| 每股收益（稀释后） | $-0.12 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ISPRRGNX
| Q4 25 | $20.3M | $30.3M | ||
| Q3 25 | $30.4M | $29.7M | ||
| Q2 25 | $20.1M | $21.4M | ||
| Q1 25 | $26.2M | $89.0M | ||
| Q4 24 | $41.8M | $21.2M | ||
| Q3 24 | $39.3M | $24.2M | ||
| Q2 24 | $37.3M | $22.3M | ||
| Q1 24 | $30.0M | $15.6M |
净利润ISPRRGNX
| Q4 25 | $-6.6M | $-67.1M | ||
| Q3 25 | $-3.3M | $-61.9M | ||
| Q2 25 | $-14.8M | $-70.9M | ||
| Q1 25 | $-10.9M | $6.1M | ||
| Q4 24 | $-8.0M | $-51.2M | ||
| Q3 24 | $-5.6M | $-59.6M | ||
| Q2 24 | $-3.5M | $-53.0M | ||
| Q1 24 | $-5.9M | $-63.3M |
毛利率ISPRRGNX
| Q4 25 | 17.1% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 12.3% | — | ||
| Q1 25 | 18.2% | — | ||
| Q4 24 | 18.5% | 70.2% | ||
| Q3 24 | 19.5% | 48.8% | ||
| Q2 24 | 28.3% | 52.5% | ||
| Q1 24 | 20.4% | 72.6% |
营业利润率ISPRRGNX
| Q4 25 | -33.9% | -190.0% | ||
| Q3 25 | -8.9% | -176.3% | ||
| Q2 25 | -72.7% | -296.3% | ||
| Q1 25 | -40.4% | 13.6% | ||
| Q4 24 | -17.6% | -242.1% | ||
| Q3 24 | -13.4% | -256.6% | ||
| Q2 24 | -9.2% | -251.3% | ||
| Q1 24 | -18.8% | -408.8% |
净利率ISPRRGNX
| Q4 25 | -32.5% | -221.3% | ||
| Q3 25 | -10.7% | -208.3% | ||
| Q2 25 | -73.4% | -331.8% | ||
| Q1 25 | -41.5% | 6.8% | ||
| Q4 24 | -19.1% | -241.3% | ||
| Q3 24 | -14.2% | -246.3% | ||
| Q2 24 | -9.4% | -237.7% | ||
| Q1 24 | -19.7% | -405.4% |
每股收益（稀释后）ISPRRGNX
| Q4 25 | $-0.12 | $-1.30 | ||
| Q3 25 | $-0.06 | $-1.20 | ||
| Q2 25 | $-0.26 | $-1.38 | ||
| Q1 25 | $-0.19 | $0.12 | ||
| Q4 24 | $-0.14 | $-0.99 | ||
| Q3 24 | $-0.10 | $-1.17 | ||
| Q2 24 | $-0.07 | $-1.05 | ||
| Q1 24 | $-0.11 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-7.7M | $102.7M |
| 总资产 | $84.4M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ISPRRGNX
| Q4 25 | $17.6M | $230.1M | ||
| Q3 25 | $22.7M | $274.2M | ||
| Q2 25 | $24.4M | $323.3M | ||
| Q1 25 | $23.5M | $267.9M | ||
| Q4 24 | $34.4M | $234.7M | ||
| Q3 24 | $37.7M | $255.5M | ||
| Q2 24 | $35.1M | $290.4M | ||
| Q1 24 | $39.5M | $338.7M |
股东权益ISPRRGNX
| Q4 25 | $-7.7M | $102.7M | ||
| Q3 25 | $-1.8M | $161.5M | ||
| Q2 25 | $604.7K | $213.7M | ||
| Q1 25 | $14.8M | $274.2M | ||
| Q4 24 | $24.2M | $259.7M | ||
| Q3 24 | $30.7M | $301.4M | ||
| Q2 24 | $34.5M | $348.3M | ||
| Q1 24 | $35.9M | $390.7M |
总资产ISPRRGNX
| Q4 25 | $84.4M | $453.0M | ||
| Q3 25 | $96.4M | $525.2M | ||
| Q2 25 | $102.2M | $581.0M | ||
| Q1 25 | $115.7M | $490.9M | ||
| Q4 24 | $132.0M | $466.0M | ||
| Q3 24 | $129.0M | $519.1M | ||
| Q2 24 | $122.6M | $569.4M | ||
| Q1 24 | $108.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-4.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | -19.9% | -174.0% |
| 资本支出强度资本支出/营收 | 0.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-14.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ISPRRGNX
| Q4 25 | $-4.0M | $-52.3M | ||
| Q3 25 | $-1.2M | $-56.0M | ||
| Q2 25 | $4.7M | $-49.3M | ||
| Q1 25 | $-12.5M | $33.6M | ||
| Q4 24 | $-3.2M | $-31.6M | ||
| Q3 24 | $3.6M | $-40.5M | ||
| Q2 24 | $-1.4M | $-45.5M | ||
| Q1 24 | $3.4M | $-55.5M |
自由现金流ISPRRGNX
| Q4 25 | $-4.0M | $-52.8M | ||
| Q3 25 | $-1.2M | $-56.5M | ||
| Q2 25 | $3.7M | $-49.7M | ||
| Q1 25 | $-12.7M | $32.6M | ||
| Q4 24 | $-3.2M | $-32.7M | ||
| Q3 24 | $3.3M | $-40.9M | ||
| Q2 24 | $-2.2M | $-46.0M | ||
| Q1 24 | $3.3M | $-56.0M |
自由现金流率ISPRRGNX
| Q4 25 | -19.9% | -174.0% | ||
| Q3 25 | -3.9% | -189.9% | ||
| Q2 25 | 18.6% | -232.8% | ||
| Q1 25 | -48.4% | 36.6% | ||
| Q4 24 | -7.7% | -154.2% | ||
| Q3 24 | 8.5% | -168.9% | ||
| Q2 24 | -5.9% | -206.2% | ||
| Q1 24 | 10.9% | -358.5% |
资本支出强度ISPRRGNX
| Q4 25 | 0.3% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 4.8% | 1.8% | ||
| Q1 25 | 0.7% | 1.2% | ||
| Q4 24 | 0.1% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 2.0% | 2.1% | ||
| Q1 24 | 0.3% | 3.6% |
现金转化率ISPRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISPR
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
